# Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Canonical URL: https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-inflammator-7b227a02
Ticker: ACRS
Company: Aclaris Therapeutics
Source: Aclaris Therapeutics
Published: 2026-04-08 12:30 EST
## Summary

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference...

## Article Body
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com . The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 wroberts@aclaristx.com
## Recent Company News
- 2026-05-28 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conf-a0a234d5) — Source: Aclaris Therapeutics
- 2026-05-08 12:30 EST — [Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-participate-in-the-2026-bank-of-america-healthcare-confe-33f392b6) — Source: Aclaris Therapeutics
- 2026-05-07 10:59 EST — [Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-reports-first-quarter-2026-financial-results-and-provides-c-c157b37c) — Source: Aclaris Therapeutics
- 2026-04-28 10:30 EST — [Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-fro-968484cf) — Source: Aclaris Therapeutics
- 2026-04-27 20:45 EST — [Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-to-provide-clinical-update-on-key-biologic-and-oral-inhibit-c67a7f91) — Source: Aclaris Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)